What is the recommended treatment and prognosis for a patient with an ejection fraction of 25% who requires supplemental oxygen?

Treatment and Prognosis for EF 25% Requiring Supplemental Oxygen

A patient with ejection fraction of 25% requiring supplemental oxygen has severe heart failure with reduced ejection fraction (HFrEF) and should be triaged to intensive care unit (ICU) or coronary care unit (CCU) for immediate stabilization, followed by aggressive guideline-directed medical therapy (GDMT) with a guarded prognosis of approximately 26-39% mortality at 3 years. 1, 2

Immediate Triage and Stabilization

This patient meets ICU admission criteria based on oxygen requirement (SaO2 < 90% despite supplemental oxygen). 1

• Triage to ICU/CCU is mandated when patients require supplemental oxygen with SaO2 < 90%, which indicates compromised respiratory status requiring intensive monitoring. 1
• Additional high-risk features to assess include systolic BP < 90 mmHg, heart rate < 60 or > 120 bpm, evidence of organ hypoperfusion (oliguria, cold peripheries, altered mental status, lactate > 2 mmol/L), or use of accessory muscles for breathing. 1
• Deliver oxygen via non-rebreather mask at 15 L/min if SpO2 is below 85%, targeting peripheral oxygen saturation of 94-98% in previously healthy patients. 3

Critical caveat: Supplemental oxygen is indicated for hypoxemic patients (SpO2 < 90-94%), but routine oxygen in normoxemic heart failure patients may be detrimental due to hyperoxia-induced vasoconstriction and increased oxidative stress. 4

Guideline-Directed Medical Therapy (GDMT)

Once hemodynamically stabilized, initiate all four pillars of GDMT with target dose titration within 6-12 weeks: 5

• Angiotensin receptor-neprilysin inhibitor (ARNI) or ACE inhibitor/ARB if ARNI not tolerated 5
• Beta blocker (carvedilol, metoprolol succinate, or bisoprolol) 5
• Mineralocorticoid receptor antagonist (MRA) (spironolactone or eplerenone) 5
• Sodium-glucose cotransporter-2 (SGLT2) inhibitor (dapagliflozin or empagliflozin) 5

These four medication classes have proven mortality benefit and should be initiated rapidly, not sequentially. 5

In-Hospital Monitoring Requirements

Standard monitoring protocols for hospitalized HFrEF patients include: 1

• Daily weights with accurate fluid balance charting 1
• Daily measurement of renal function (BUN, creatinine) and electrolytes 1
• Continuous noninvasive monitoring of pulse, respiratory rate, and blood pressure 1
• Pre-discharge natriuretic peptide measurement for post-discharge planning (falling levels predict better 6-month outcomes) 1

Monitor for GDMT-related adverse effects requiring dose adjustment: 5

• Hypotension (common with ARNI and beta blockers) 5
• Hyperkalemia (MRA and ARNI) 5
• Worsening renal function (may improve or deteriorate with diuresis) 1, 5

Secondary and Adjunctive Therapies

Consider additional therapies for persistent symptoms or specific indications: 5

• Intravenous iron replacement if iron deficiency present (improves functional status and quality of life) 5
• Digoxin for rate control in atrial fibrillation or persistent symptoms 5
• Hydralazine plus isosorbide dinitrate particularly in Black patients or those intolerant to ARNI/ACE-I/ARB 5
• Ivabradine if heart rate > 70 bpm on maximally tolerated beta blocker 5
• Vericiguat for worsening heart failure despite GDMT 5

Device Therapy Consideration

Evaluate for implantable cardioverter-defibrillator (ICD) and cardiac resynchronization therapy (CRT): 5

• ICD indicated if EF ≤ 35% after 3 months of optimal medical therapy to reduce sudden cardiac death risk 5
• CRT-D (biventricular pacing with defibrillator) if QRS duration prolonged (≥ 150 ms with LBBB pattern) 5

Surgical Revascularization

If significant coronary artery disease is present, coronary artery bypass grafting (CABG) offers superior long-term survival compared to medical therapy alone in patients with EF < 25%. 6

• Eight-year survival with CABG was 61% versus 29% with medical therapy alone in patients with EF < 25% and significant coronary disease. 6
• This represents a critical decision point requiring coronary angiography if not already performed. 6

Prognosis

The prognosis for EF 25% is guarded with high mortality risk: 2

• Three-year mortality approaches 74% in patients with EF ≤ 20% in historical cohorts. 2
• Important prognostic insight: Once EF falls below 20-25%, the absolute EF value loses predictive power for mortality; instead, peak VO2 (functional capacity) becomes the stronger predictor. 2
• High admission BUN (≥ 43 mg/dL), low systolic BP (< 115 mmHg), and elevated creatinine (≥ 2.75 mg/dL) identify the highest-risk population with 22% in-hospital mortality. 1

Discharge Criteria and Follow-Up

Patients are medically fit for discharge when: 1

• Hemodynamically stable and euvolemic 1
• Established on evidence-based oral medications 1
• Stable renal function for at least 24 hours before discharge 1
• Provided with tailored education about self-care 1

Mandatory post-discharge follow-up structure: 1

• Enrollment in disease management program 1
• General practitioner visit within 1 week of discharge 1
• Hospital cardiology team visit within 2 weeks of discharge 1
• Ongoing care within multi-professional heart failure service 1

Critical Pitfalls to Avoid

• Do not delay ICU admission in patients with oxygen requirement—clinical judgment often underestimates risk. 1
• Do not use oxygen routinely if patient is normoxemic (SpO2 > 94%)—this may cause harm through vasoconstriction. 4
• Do not focus solely on improving EF as a therapeutic goal in patients with EF < 25%—functional capacity (peak VO2) is more prognostically important. 2
• Do not discharge patients before achieving 24 hours of hemodynamic and renal stability on oral medications. 1
• Do not fail to initiate all four GDMT pillars rapidly—sequential initiation delays mortality benefit. 5